Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968045648> ?p ?o ?g. }
- W1968045648 endingPage "1266" @default.
- W1968045648 startingPage "1247" @default.
- W1968045648 abstract "Introduction: The survival of patients with glioblastoma (GBM), which is the most common primary brain malignancy, remains poor with current treatment modalities. However, an enhanced understanding of gliomagenesis is supporting the development of targeted molecular therapies with the potential for improving clinical outcomes. Areas covered: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) initiate key signaling pathways in GBM; however, trials with anti-EGFR agents have failed to show improved outcomes. Bevacizumab, a monoclonal antibody targeting VEGF, remains the only FDA-approved molecular drug in GBM; yet its use has only improved progression-free survival without any improvement in overall survival. We review the evidence supporting the continued evaluation of targeted molecular therapies in recurrent GBM. In addition, newer potential therapies targeting other signaling pathways, heat shock proteins and proteosomes, as well as the concept of targeting glioma stem cells are discussed. Expert opinion: The complex genetic origin of GBM makes it challenging to identify molecular subsets that may benefit from specific targeted therapies. Pathway inhibition, via multisite kinase inhibitors or a carefully selected combination of molecular drugs with or without cytotoxic agents, is currently undergoing evaluation in clinical trials and may improve outcomes in these patients." @default.
- W1968045648 created "2016-06-24" @default.
- W1968045648 creator A5026857919 @default.
- W1968045648 creator A5035416012 @default.
- W1968045648 creator A5039448543 @default.
- W1968045648 creator A5065263618 @default.
- W1968045648 creator A5073787018 @default.
- W1968045648 date "2012-06-25" @default.
- W1968045648 modified "2023-10-02" @default.
- W1968045648 title "Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions" @default.
- W1968045648 cites W131042380 @default.
- W1968045648 cites W1556788203 @default.
- W1968045648 cites W179710673 @default.
- W1968045648 cites W1858161324 @default.
- W1968045648 cites W1940514332 @default.
- W1968045648 cites W1959628099 @default.
- W1968045648 cites W1964321121 @default.
- W1968045648 cites W1965559724 @default.
- W1968045648 cites W1966021810 @default.
- W1968045648 cites W197014098 @default.
- W1968045648 cites W1971031493 @default.
- W1968045648 cites W1977223089 @default.
- W1968045648 cites W1977392502 @default.
- W1968045648 cites W1978041336 @default.
- W1968045648 cites W1983244945 @default.
- W1968045648 cites W1983343441 @default.
- W1968045648 cites W1984041688 @default.
- W1968045648 cites W1984383995 @default.
- W1968045648 cites W1994089045 @default.
- W1968045648 cites W1995502732 @default.
- W1968045648 cites W1996679013 @default.
- W1968045648 cites W1996859043 @default.
- W1968045648 cites W1999574985 @default.
- W1968045648 cites W2001355942 @default.
- W1968045648 cites W2002727873 @default.
- W1968045648 cites W2004471993 @default.
- W1968045648 cites W2010750753 @default.
- W1968045648 cites W2010956784 @default.
- W1968045648 cites W2012172048 @default.
- W1968045648 cites W2013094135 @default.
- W1968045648 cites W2013878898 @default.
- W1968045648 cites W2014169920 @default.
- W1968045648 cites W2014994637 @default.
- W1968045648 cites W2018016372 @default.
- W1968045648 cites W2020259422 @default.
- W1968045648 cites W2021288638 @default.
- W1968045648 cites W2025183726 @default.
- W1968045648 cites W2028224222 @default.
- W1968045648 cites W2028704745 @default.
- W1968045648 cites W2031671750 @default.
- W1968045648 cites W2037454422 @default.
- W1968045648 cites W2038657036 @default.
- W1968045648 cites W2039872271 @default.
- W1968045648 cites W2041098455 @default.
- W1968045648 cites W2046507292 @default.
- W1968045648 cites W2048758017 @default.
- W1968045648 cites W2049484790 @default.
- W1968045648 cites W2053318593 @default.
- W1968045648 cites W2053383685 @default.
- W1968045648 cites W2056535857 @default.
- W1968045648 cites W2060551076 @default.
- W1968045648 cites W2061288640 @default.
- W1968045648 cites W2061343912 @default.
- W1968045648 cites W2061701210 @default.
- W1968045648 cites W2069806273 @default.
- W1968045648 cites W2070705072 @default.
- W1968045648 cites W2072483737 @default.
- W1968045648 cites W2074823829 @default.
- W1968045648 cites W2076424556 @default.
- W1968045648 cites W2079677696 @default.
- W1968045648 cites W2082210456 @default.
- W1968045648 cites W2083083094 @default.
- W1968045648 cites W2084469720 @default.
- W1968045648 cites W2086216067 @default.
- W1968045648 cites W2088056286 @default.
- W1968045648 cites W2091707974 @default.
- W1968045648 cites W2092409918 @default.
- W1968045648 cites W2093783077 @default.
- W1968045648 cites W2094962376 @default.
- W1968045648 cites W2096287682 @default.
- W1968045648 cites W2096415778 @default.
- W1968045648 cites W2098588666 @default.
- W1968045648 cites W2098983401 @default.
- W1968045648 cites W2099431752 @default.
- W1968045648 cites W2099803844 @default.
- W1968045648 cites W2103334409 @default.
- W1968045648 cites W2104743043 @default.
- W1968045648 cites W2105100844 @default.
- W1968045648 cites W2110254666 @default.
- W1968045648 cites W2114438728 @default.
- W1968045648 cites W2115078677 @default.
- W1968045648 cites W2115516828 @default.
- W1968045648 cites W2116622644 @default.
- W1968045648 cites W2117941094 @default.
- W1968045648 cites W2121889629 @default.
- W1968045648 cites W2121935146 @default.
- W1968045648 cites W2123808042 @default.
- W1968045648 cites W2124078079 @default.